S16 Posters

Methods: The NHIC price list for a consultation of a gynaecologist for taking a Papanicolaou smear and for the cytologic interpretation is applied to 1.573.000 women aged 25 to 64 years from the Flemish Region. Information on actual attendance to screening and the relative contribution of the involved professional groups, and on the reason for the last cervical smear are derived from a recent cross-sectional study. Corrections are made for women who underwent total hysterectomy. Costs for the organisation are estimated from financial reports of the ongoing Flemish Cervical Cancer Screening Programme aiming to reach 85% of the target population. The total yearly NHIC expenses and the cost per screened woman for both approaches are compared.

Results: About 1,200,000 screening tests per 3 years or 400.000 annual smears are needed to cover the target population at 85 %. The total expences for all activities are calculated to be 485 million Belgian Francs (BEF, 40 BEF equals 1 ECU), including total estimated costs for the organisation of call-recall and registration. In 1994, about 0.67 million smears (essentially opportunistic) were interpreted from women resident in the Flemish Region. The total NHIC costs of spontaneous screening for that year is estimated at 675 million BEF. The difference between the two approaches is 190 million BEF by year. The proportion of women having had a smear in that period is assessed at about 80 %. The mean annual screening cost by covered woman is 47 % higher in a health system where screening is essentially opportunistic than in an organised context.

<u>Discussion</u>: Health authorities should realise that structural tariff differentiation and integration of cervical cancer screening in primary health care might further increase the cost gap between the spontaneous and the organised alternative.

Arbyn Marc, Epidemiologist, Coordinator Flemish Cervical Cancer Screening Programme, Scientific Institute of Public Health Louis Pasteur, J. Wytsman Street 14, 1050 Brussels, Belgium, E-mail: M.Arbyn@epil.ihe.be

PP4. Cost-effectiveness of radionuclide bone scanning to rule out asymptomatic bone metastases in clinically operable non-small cell lung cancer

Arican A, Dinçol D, Samur M, Demirkazlk A, Sencan O, Akbulut H, Karaoguz H, Çay F, Içli F

Department of Medical Oncology, Ankara University, Faculty of Medicine

<u>Background:</u> In patients with clinically operable non-small cell lung cancer (NSCLC) who have normal serum calcium, alkaline phosphatase (AP) level and upper abdominal computed tomography and no bone pain, routine radionuclide bone scanning (BS) to rule out unsuspected bone metastases has never been shown to be cost-effective. In this study we tried to evaluate the cost-effectiveness of routine preoperative use of BS in patients with NSCLC.

Methods: We performed BS in 34 patients with NSCLC who have no bone pain, normal serum calcium and AP levels. Mean cost of operative procedure including preoperative evaluation, operation and postoperative periods of all patients was calculated. On the other hand we calculated a supposed mean cost assuming all 34 patients were operated without BS and compared to the previous mean cost.

Results: Eight of the patients were stage-I, 3 were stage-II, 23 were stage-Illa and all considered to be operable before BS. None had bone pain, high serum calcium or AP. We evaluated all the patients with BS and found pathologic activity in 17 of them. The areas of pathologic activities were evaluated with direct X-ray films. In 5 of them bone metastases were confirmed, in 4 benign lesions were diagnosed. Other 8 patients with positive BS but negative x-ray, pathologic activity detected-bone sites were evaluated with computed tomography. Of these 8 patients 5 were proven to be metastatic and 3 were not. As a result in 34 patients considered operable before BS, 10 (29.4%) were found to have bone metastases and remaining 24 were operated with curative intend. Mean cost of actual evaluation of all patients was \$628, whereas supposed mean cost assuming 34 patients were operated without BS was \$803. There was a statistically significant cost difference favoring BS before operation (p=0.017). Besides, 10 of the patients were prevented from unnecessary operative mortality and morbidity.

<u>Discussion</u>: With this result, we may recommend routine radionuclide BS in preoperative staging of NSCLC patients.

Arican A, 2 Etap Eston Sitesi, 50. Sokak No:11/5, 06374 Eryaman-Ankara, Turkev

PP5. Teicoplanin or vancomycin in febrile neutropenic children with cancer: A randomized cost effectiveness study

Aupérin A, Capelli C, Benhamou E, Pinna A, Peeters P, Atlani C, Hartmann

Institut Gustave-Roussy, Villejuif, France; Benefit International, Genneviliers, France; Laboratoires Casenne-Division Hospitalière Marion Merell, Paris, France

Aim: To compare two antibiotic regimens, one including teicoplanin and the other including vancomycin as empirical therapies for febrile neutropenic children with cancer treated with conventional chemotherapy. The two glycopeptides have equivalent bacterial efficacy. Teicoplanin is more expensive than vancomycin but it is delivered once a day whereas vancomycin is delivered four times per day.

Method: Randomized trial in a department of pediatric oncology. Febrile neutropenic children received ceftazidime (90 mg/kg/day) associated with teicoplanin 10 mg/kg once daily or with vancomycin 10 mg/kg every 6 hours.

Endpoints: Number of hours of sleep per night assessed by nurse during hospitalisation. Cost of the therapy: cost of all the drugs received (acquisition cost, delivery costs) and cost of laboratory and radiological exams. Drug cost included prescription-related supplies, equipment and salaries. Time spent for drug preparation and administration was determinated by several direct measures for each drug.

Results: From January 95 to May 96, 67 children were randomized. 65 children were evaluable (32 in the teicoplanin group and 33 in the vancomycin group). The number of hours of sleep per night did not differ between the two groups: 7.0 hours in the teicoplanin group and 7.2 hours in the vancomycin group. The cost of all the antibiotics was higher in the teicoplanin group than in the vancomycin group (p = 0.006). The difference of median costs between the two groups was around 1 600 FF for a 6 day median treatment duration. This difference was due to the difference between teicoplanin and vancomycin (drug and delivery costs). The costs related to the other antibiotics did not differ between the two groups. Total costs (drugs and exams) did not significantly differ between the two groups (p = 0.18) although the size of the difference in median total costs was around 1 900 FF.

<u>Conclusion</u>: For febrile neutropenic children with cancer treated with conventional chemotherapy, the two antibiotic regimens were not different in terms of sleep but the cost minimization analysis showed that the regimen including vancomycin is better than the one including teicoplanin.

Aupérin A, Département de Biostatistique et d'Epidémiologie, Institut Gustave-Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France

PP6. Medico-economic evaluation of the cost of education in a cancer center

Bercez C¹, Michel J², Bonneterre ME¹, Morel S¹, Bonneterre J¹

Centre Oscar Lambret, Lille, France; ²Hadassah University Hospital Mt Scopus, Jerusalem, Israel

<u>Background</u>: Our aim was to identify the cost of educational activities, defined as all time spent by the center for student training, teaching for University degrees, and permanent professional education. Organization, preparation, and examination time was added to the duration of each specific activity, research work was excluded, and so was education when reimbursed by the University.

Method: Data were collected on a questionnaire, sent to each physician, pharmacist, scientist, head nurse, physiotherapist, and manager in the center. Information had to be given retrospectively on the activities of the previous year: from September 1, 1995 to August 31, 1996. The answers